Effects of complement activation products on the synthesis of decay accelerating factor and membrane cofactor protein by human mesangial cells

Fernando G Cosio, Toru Shibata, Brad H. Rovin, Daniel J. Birmingham

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We previously demonstrated that activation of terminal complement components (C8 and/or C9) increases the synthesis and expression of decay accelerating factor (DAF) on human glomerular cells. DAF is a cell membrane-associated complement regulatory protein that inhibits complement activation on cell surfaces. In the present studies we evaluated, first, the mechanism by which complement activation stimulates DAF synthesis, and second, the effect of complement activation on the synthesis, and expression of membrane cofactor protein (MCP), another complement regulatory protein, by human mesangial cells (HMC) in culture. Complement activation by immune complexes resulted in increased DAF mRNA levels by at least two mechanisms: deposition of activated C3 on HMC and generation of soluble complement activation products, specifically C5a. The increase in DAF mRNA levels induced by activated C3 or C5a was short lived (less than 4 hr). In contrast, the up-regulation of DAF mRNA levels induced by activation of the complete complement cascade persisted for at least eight hours. The effect of complement activation on DAF mRNA levels was not affected by cycloheximide, a protein synthesis inhibitor. However, cycloheximide alone resulted in a significant up-regulation of DAF mRNA levels on HMC. In contrast to those findings, complementary activation did not cause an up-regulation of MCP mRNA, nor an increase in the synthesis of this protein. However, by FACS, complement produced a small but significant increase of MCP protein levels on HMC. In conclusion, both MCP and DAF are present on HMC. Several activated complement components are capable of increasing DAF mRNA levels, but DAF protein levels increase only after activation of the whole complement cascade. Complement activation has no effects on the synthesis of MCP.

Original languageEnglish (US)
Pages (from-to)986-992
Number of pages7
JournalKidney International
Volume46
Issue number4
StatePublished - Oct 1994
Externally publishedYes

Fingerprint

CD55 Antigens
Mesangial Cells
Complement Activation
CD46 Antigens
Messenger RNA
Up-Regulation
Cycloheximide
Complement C8
Complement System Proteins
human CD46 protein
Complement C9
Proteins
Protein Synthesis Inhibitors
RNA Stability
Antigen-Antibody Complex
Membrane Proteins

ASJC Scopus subject areas

  • Nephrology

Cite this

Effects of complement activation products on the synthesis of decay accelerating factor and membrane cofactor protein by human mesangial cells. / Cosio, Fernando G; Shibata, Toru; Rovin, Brad H.; Birmingham, Daniel J.

In: Kidney International, Vol. 46, No. 4, 10.1994, p. 986-992.

Research output: Contribution to journalArticle

Cosio, Fernando G ; Shibata, Toru ; Rovin, Brad H. ; Birmingham, Daniel J. / Effects of complement activation products on the synthesis of decay accelerating factor and membrane cofactor protein by human mesangial cells. In: Kidney International. 1994 ; Vol. 46, No. 4. pp. 986-992.
@article{b1a5082d176e4946a3c9c3d66ffdd83e,
title = "Effects of complement activation products on the synthesis of decay accelerating factor and membrane cofactor protein by human mesangial cells",
abstract = "We previously demonstrated that activation of terminal complement components (C8 and/or C9) increases the synthesis and expression of decay accelerating factor (DAF) on human glomerular cells. DAF is a cell membrane-associated complement regulatory protein that inhibits complement activation on cell surfaces. In the present studies we evaluated, first, the mechanism by which complement activation stimulates DAF synthesis, and second, the effect of complement activation on the synthesis, and expression of membrane cofactor protein (MCP), another complement regulatory protein, by human mesangial cells (HMC) in culture. Complement activation by immune complexes resulted in increased DAF mRNA levels by at least two mechanisms: deposition of activated C3 on HMC and generation of soluble complement activation products, specifically C5a. The increase in DAF mRNA levels induced by activated C3 or C5a was short lived (less than 4 hr). In contrast, the up-regulation of DAF mRNA levels induced by activation of the complete complement cascade persisted for at least eight hours. The effect of complement activation on DAF mRNA levels was not affected by cycloheximide, a protein synthesis inhibitor. However, cycloheximide alone resulted in a significant up-regulation of DAF mRNA levels on HMC. In contrast to those findings, complementary activation did not cause an up-regulation of MCP mRNA, nor an increase in the synthesis of this protein. However, by FACS, complement produced a small but significant increase of MCP protein levels on HMC. In conclusion, both MCP and DAF are present on HMC. Several activated complement components are capable of increasing DAF mRNA levels, but DAF protein levels increase only after activation of the whole complement cascade. Complement activation has no effects on the synthesis of MCP.",
author = "Cosio, {Fernando G} and Toru Shibata and Rovin, {Brad H.} and Birmingham, {Daniel J.}",
year = "1994",
month = "10",
language = "English (US)",
volume = "46",
pages = "986--992",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Effects of complement activation products on the synthesis of decay accelerating factor and membrane cofactor protein by human mesangial cells

AU - Cosio, Fernando G

AU - Shibata, Toru

AU - Rovin, Brad H.

AU - Birmingham, Daniel J.

PY - 1994/10

Y1 - 1994/10

N2 - We previously demonstrated that activation of terminal complement components (C8 and/or C9) increases the synthesis and expression of decay accelerating factor (DAF) on human glomerular cells. DAF is a cell membrane-associated complement regulatory protein that inhibits complement activation on cell surfaces. In the present studies we evaluated, first, the mechanism by which complement activation stimulates DAF synthesis, and second, the effect of complement activation on the synthesis, and expression of membrane cofactor protein (MCP), another complement regulatory protein, by human mesangial cells (HMC) in culture. Complement activation by immune complexes resulted in increased DAF mRNA levels by at least two mechanisms: deposition of activated C3 on HMC and generation of soluble complement activation products, specifically C5a. The increase in DAF mRNA levels induced by activated C3 or C5a was short lived (less than 4 hr). In contrast, the up-regulation of DAF mRNA levels induced by activation of the complete complement cascade persisted for at least eight hours. The effect of complement activation on DAF mRNA levels was not affected by cycloheximide, a protein synthesis inhibitor. However, cycloheximide alone resulted in a significant up-regulation of DAF mRNA levels on HMC. In contrast to those findings, complementary activation did not cause an up-regulation of MCP mRNA, nor an increase in the synthesis of this protein. However, by FACS, complement produced a small but significant increase of MCP protein levels on HMC. In conclusion, both MCP and DAF are present on HMC. Several activated complement components are capable of increasing DAF mRNA levels, but DAF protein levels increase only after activation of the whole complement cascade. Complement activation has no effects on the synthesis of MCP.

AB - We previously demonstrated that activation of terminal complement components (C8 and/or C9) increases the synthesis and expression of decay accelerating factor (DAF) on human glomerular cells. DAF is a cell membrane-associated complement regulatory protein that inhibits complement activation on cell surfaces. In the present studies we evaluated, first, the mechanism by which complement activation stimulates DAF synthesis, and second, the effect of complement activation on the synthesis, and expression of membrane cofactor protein (MCP), another complement regulatory protein, by human mesangial cells (HMC) in culture. Complement activation by immune complexes resulted in increased DAF mRNA levels by at least two mechanisms: deposition of activated C3 on HMC and generation of soluble complement activation products, specifically C5a. The increase in DAF mRNA levels induced by activated C3 or C5a was short lived (less than 4 hr). In contrast, the up-regulation of DAF mRNA levels induced by activation of the complete complement cascade persisted for at least eight hours. The effect of complement activation on DAF mRNA levels was not affected by cycloheximide, a protein synthesis inhibitor. However, cycloheximide alone resulted in a significant up-regulation of DAF mRNA levels on HMC. In contrast to those findings, complementary activation did not cause an up-regulation of MCP mRNA, nor an increase in the synthesis of this protein. However, by FACS, complement produced a small but significant increase of MCP protein levels on HMC. In conclusion, both MCP and DAF are present on HMC. Several activated complement components are capable of increasing DAF mRNA levels, but DAF protein levels increase only after activation of the whole complement cascade. Complement activation has no effects on the synthesis of MCP.

UR - http://www.scopus.com/inward/record.url?scp=0028091924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028091924&partnerID=8YFLogxK

M3 - Article

C2 - 7532249

AN - SCOPUS:0028091924

VL - 46

SP - 986

EP - 992

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -